Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) — Working Capital to Net Assets Ratio
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) has a Working Capital to Net Assets ratio of 42.8% as of March 2026. Working capital of CN¥5.13 Billion (current assets of CN¥6.73 Billion minus current liabilities of CN¥1.60 Billion) is measured against net assets of CN¥11.99 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 603392 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Working Capital to Net Assets (2013–2025)
This chart shows how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 42.8%, reflecting working capital of CN¥5.13 Billion against net assets of CN¥11.99 Billion CNY. See Beijing Wantai Biological Pharmacy Enter liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 603392 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.6% | CN¥5.72 Billion | CN¥12.03 Billion | CN¥7.53 Billion | CN¥1.80 Billion | ▼ -3.5 pp |
| 2024 | 51.1% | CN¥6.36 Billion | CN¥12.45 Billion | CN¥8.37 Billion | CN¥2.01 Billion | ▼ -8.1 pp |
| 2023 | 59.2% | CN¥7.63 Billion | CN¥12.88 Billion | CN¥10.30 Billion | CN¥2.67 Billion | ▼ -10.0 pp |
| 2022 | 69.2% | CN¥8.69 Billion | CN¥12.56 Billion | CN¥12.18 Billion | CN¥3.49 Billion | ▲ +19.2 pp |
| 2021 | 50.0% | CN¥2.28 Billion | CN¥4.56 Billion | CN¥4.65 Billion | CN¥2.37 Billion | ▲ +5.5 pp |
| 2020 | 44.5% | CN¥1.15 Billion | CN¥2.58 Billion | CN¥1.98 Billion | CN¥829.03 Million | ▲ +19.6 pp |
| 2019 | 24.9% | CN¥393.63 Million | CN¥1.58 Billion | CN¥885.66 Million | CN¥492.03 Million | ▼ -13.5 pp |
| 2018 | 38.4% | CN¥526.29 Million | CN¥1.37 Billion | CN¥870.58 Million | CN¥344.29 Million | ▲ +17.4 pp |
| 2017 | 21.0% | CN¥188.79 Million | CN¥898.99 Million | CN¥759.93 Million | CN¥571.14 Million | ▼ -3.3 pp |
| 2016 | 24.3% | CN¥233.38 Million | CN¥959.70 Million | CN¥654.56 Million | CN¥421.18 Million | ▼ -14.6 pp |
| 2015 | 38.9% | CN¥281.47 Million | CN¥722.69 Million | CN¥584.95 Million | CN¥303.48 Million | ▼ -18.3 pp |
| 2014 | 57.2% | CN¥332.07 Million | CN¥580.32 Million | CN¥500.71 Million | CN¥168.63 Million | ▲ +8.5 pp |
| 2013 | 48.7% | CN¥186.23 Million | CN¥382.06 Million | CN¥363.32 Million | CN¥177.09 Million | — |